.gen Technologies Inc.

Local biotech Isis Pharmaceuticals reports strong results for their cholesterol therapy mipomersen, at the same time broadening potential patients from those that are homozygous for familial hypercholesterolemia to those who are heterozygous as well. Isis and partner Genzyme plan to move this treatment to market in 2011. http://www.xconomy.com/boston/2010/02/10/genzyme-and-isis-report-positive-results-for-cholesterol-lowering-drug/

A spectacular result for local biotech Isis Pharmaceuticals with their cholesterol candidate mipomercen. This trial saw an average 25% reduction in LDL for genetically suseptible patients, with some seeing reductions of 70 – 80%. That’s great news for Isis and marketing partner Genzyme. http://www.fiercebiotech.com/story/isis-cholesterol-drug-hits-bulls-eye-pivotal-trial/2009-11-17?utm_medium=nl&utm_source=internal